Chemical reactivity-absorption, retention, metabolism, and elimination of hexachlorocyclopentadiene. by Mehendale, H M
Environmental Health Perspectives
Vol. 21, pp. 275-278, 1977
Chemical Reactivity-Absorption,
Retention, Metabolism, and Elimination
of Hexachiorocyclopentadiene
by H. M. Mehendale*
Hexachlorocyclopentadiene is eliminated from the body efficiently by urinary excretion. Although
direct evidence is not available, it appears that expiration my be another important route ofelimination.
Of the administered dose 9%o is excreted in the bile in 1 hr, approximately equal to the amount offecal
excretion in 7 days, suggesting enterohepatic circulation. After a single dose, HCPD decays from the
blood biexponentially with a terminal phase half-life of 60 min. Of the tissues analyzed kidney, followed
by liver, concentrate HCPD 1 hr or 7 days after exposure to any significantextent. Subceliularly, HCPD is
predominantiy associated with cytosol fractions of both kidney as well as liver, observations consistent
with rapid elimination ofHCPD after a single exposure..Preexposure to HCPD (50 mg/kg-day for 3 days)
resulted in unaltered blood decay curves and biliary excretion, but increased the concentration in the
kidneys after a single subsequent challenge.
Introduction
Hexachlorocyclopentadiene (HCPD) (I) is pre-
chlorinated, highly reactive compound, used as a
building block in chemicals having biocidal and
fire-retarding features. It is used in the manufacture
of most commonly used cyclodiene pesticides such
as chlordane, heptachlor (Table 1), heptachlor
epoxide (1), etc. In addition, mirex, a pesticide used
in the control offire ants, and its analog kepone, are
also synthesized by condensing two molecules of
HCPD (1). Fungicidal properties of HCPD have
also been reported (2). It is also used in the synthe-
sis of chlorendic anhydride and acid, chemicals
comprising the basis for chemical and high-heat re-
sistant coatings and resins with flame retardant
properties. Mirex, for example, possesses flame-
retardant properties in addition to insecticidal activ-
ity (3). A number of other industrial chemicals are
formed from adduct products of HCPD with ali-
phatic (4) and aromatic dienophilic compounds (1,
5). Other adduct products of HCPD with poly-
nuclear aromatic hydrocarbons such as naphthalene
and arthracene form the basis for subsequent sub-
stitution of the aromatic rings to yield several com-
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pounds used in the dye industry (5). HCPD is also
used as a vulcanizing agent for rubber and diene
elastomers (1). Although the annual U. S. produc-
tion and usage is not a matter ofpublished record, a
guarded estimate of50 million pounds may be made
based on the known annual rates of production of
various cyclodiene insecticides (6).
Table 1. Comparative toxicities of HCPD and
some cyclodiene insecticides.
Ratio of LD50
Oral LD.", to maximum
mg/kg tolerated dose
Pesticide Rats Mice Rats Mice
Allodan 940 750 1.9 1.5
Chlordan 500 225 1.6 4.5
Thiodan 105 75 2.4 3.7
Heptachlor 82 210 3.3 4.2
Aldrin 42 18 1.4 1.8
Dieldrin 40 24 1.3 2.4
Isodrin 10 9 2.5 2.9
Endrin 9 9 1.7 3.0
HCPD 300 505 N.A. N.A.
aData of Spynu (7).
Chemical Reactivity
The Diels-Alder reaction is a well-known con-
densation reaction in which a compound containing
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bonded compound. HCPD shows an unexpected
tendency to undergo the Diels-Alder reaction with
many dienophiles at temperatures between 200 and
200°C. It condenses even with simple olefins, which
normally do not react with dienes and with polynu-
clear aromatic hydrocarbons such as naphthalene
and anthracene. Examples of such adduct products
are numerous (1, 5). Equimolar proportions of
HCPD and bicycloheptadiene (BCHD) [Eq. (1)]
react to give hexachlorotetracyclododecadiene (Al-
drin) which is a parent compound for a series of
cyclodiene insecticides. Another example of
HCPD-14C. An average of approximately 33% of
the administered dose was excreted in the urine
after 7 days (Fig. 1). About 87% of that was elimi-
nated during the first 24 hr after the administration
of HCPD. Fecal excretion accounted for about
10%o of the administered dose (Fig. 2). Nearly 60Wo
ofthe 7-day fecal excretion occurred during the day
1, and after the day 3 only trace amounts of
HCPD-derived 14C was eliminated in the feces.
Tissues retained only trace amounts ofHCPD after
7 days. Kidney retained 0.5% of the dose followed
by liver which contained less than 0.5% ofthe dose.
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Diels-Alder reaction may be seen in the
dihexachloropentadiene adduct (DHA) formed
from HCPD and naphthalene [Eq. (2)]. The ad-
ducts with similar polynuclear aromatics are used
as starting materials in the synthesis of variously
(e.g., nitration, sulfonation, chlorination and other
mixed reactions) substituted intermediates used in
the dye industry and other industrial applications.
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FIGURE 1. Urinary excretion ofHCPD-14C/derived radiolabel in
male rats. Four animals were administered HCPD-14C
(1 ,uCi, 6 mg/kg) orally and housed in individual metabolism
cages. Daily urine samples were analyzed for total radiolabel.
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HCPD-U- 14C (5 umole, 1 ,uCi per animal) was
administered to four male Sprague-Dawley rats
(225-250 g) by oral intubation as a solution in 0.2 ml
corn oil. The animals were maintained in
metabolism cages with food and water ad libitum.
Daily urine and fecal samples were collected. After
7 days the animals were sacrificed and majortissues
and organs were removed, homogenized in distilled
water and radioassayed. Urine and powdered feces
samples were also radioassayed for total 14C.
Figures 1 and2 illustrate the pattern ofurinary and
fecal excretion of the 14C material derived from
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FIGURE 2. Fecal excretion of HCPD-14C-derived radiolabel in
male rats. Four animals were administered HCPD-14C (1
,uCi, 6 mg/kg) orally and housed in individual metabolism
cages. Daily fecal samples were analyzedfortotal radiolabel.
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+ H2Other tissues-fat, lung, muscle, blood, etc.-had
smaller traces of the radiolabel, suggesting that
perhaps better than halfofthe administered HCPD
was eliminated by routes other than urine and feces.
It is assumed that elimination by respiratory tract,
followed by urinary and fecal routes, constitute
major routes of elimination for HCPD.
Metabolism
Since urine contained approximately one third of
the administered HCPD, the nature of the radioac-
tivity excreted in urine was examined for possible
metabolites. Urine was twice extracted with two
volumes of (9:1) hexane; isopropanol mixture. Ap-
proximately 70%o of the radioactivity in urine was
organo-extractable leaving the remainder as water
soluble material. The organic extract was concen-
trated and applied on silica gel G TLC plates. The
plates were developed in three solvent systems: (1)
cyclohexane-acetone, 80:20; (2) benzene-acetone,
9:1; (3) hexane-isopropanol, 9:1. The radioactive
spots were visualized by autoradiography on medi-
cal x-ray film. These results suggest at least four
metabolites of HCPD. These metabolites have not
been identified and characterized. The quantitative
aspects of these and water-soluble metabolites of
HCPD will be the subject of future investigations.
Disposition and Biliary Excretion
of HCPD-14C
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Male rats were anesthesized with pentobarbital
sodium (45 mg/kg, IP) and femoral vein, femoral
artery, and common bile duct were cannulated.
Approximately 1 ,uCi (5 ,mmole) of HCPD-14C was
injected via femoral vein. Timed samples of blood
and bile were collected for 1 hr. The radioactivity
from blood decayed biexponentially (Fig. 3) with
the terminal phase half-life of 1 hr. Approximately
9%ofthe administered dose was excreted inthebile
in 1 hr (Fig. 4). The nature ofthe 14C material in the
bile has not been examined.
In other experiments, effect of pre-exposure to
HCPD (50 mg/kg/day for 3 days, PO, in corn oil) on
the biliary excretion of HCPD-14C derived radio-
label was investigated. Biliary excretion of
HCPD-14C was unaltered in these experiments.
Also, no discernible changes were observed in the
blood concentration decay curve for HCPD-14C.
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FIGURE 3. Biexponential decay of HCPD-14C in the blood of
male rats. Rats were cannulated under pentobarbital (45
mg/kg, IP) anesthesia. HCPD-14C(l ,ACi, 5 j,mole) was in-
jected through the femoral vein, and timed blood samples
obtained through femoral artery were analyzed for total
radiolabel. Results presented are average ofthree individual
determinations.
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FIGURE 4. Biliary excretion ofHCPD-14C. Animals werecannu-
lated under pentobarbital (45 mg/kg, IP) anesthesia.
HCPD-14C (I ,uCi, 5 ymole) was injected via femoral vein,
and timed bile samples were collected via common bile duct
and analyzed for total radiolabel content. Results are means
± SEM of three individual determinations.
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HCPD-14C
At the end of the above experiments animals
were sacrificed and liver and kidneys were re-
moved. Total 14C content of these organs was esti-
mated by radioassaying samples of tissue homoge-
nates. The distribution of radioactivity in various
subcellular fractions was examined by radioassay-
ing various centrifugation fractions of the liver and
kidney homogenates. The kidney contained higher
concentration of HCPD than the liver, although by
virtue of the size, liver contained more HCPD
equivalents (Table 2). HCPD-equivalents in vari-
ous subcellular fractions were expressed as percen-
tage ofthe total in the whole homogenate (Tables 3
and 4). Kidney cytosol (105,OOOg supernatant)
fraction contained over 93% of the radioactivity
(Table 3). These data are consistent with the rapid
urinary excretion of this compound. Although to a
slightly lesser extent, most of the radiolabel (68%)
was present in the cytosol fraction (105,000g super-
natant) (Table 4) of the liver. Pre-exposure to the
HCPD (50 mg/kg/day for 3 days, PO) resulted in
increased concentration of HCPD in the kidneys
after a single challenge of HCPD-14C (Table 5).
Despite the larger size ofthe liver, kidneys retained
similar amounts of HCPD-14C material in terms of
total quantity. The hepatic concentration of
HCPD-14C was unaltered by pre-exposure to
HCPD. The time course ofthe subcellular distribu-
tion has not been examined. Also additional infor-
mation may be obtained on the nature of binding,
Table 2. Renal and hepatic concentration of HCPD.G
HCPD-14C after 60 min, ,umole x 102
Organ Per organ Per g tissue
Liver 26±2.0 2 0.1
Kidney 14 ± 0.5 5 ± 0.3
aTissue conents were determined 60 min after IV administra-
tion of 5 ,umole HCPD-14C. Results are means + SEM offour
individual determinations.
Table 3. Subceilular distribution of HCPD-14C in
kidney fractions.a
Concn ofkidney (.umole/g),
Fraction % of 14C in whole homogenate
Whole homogenate 100
900 g 2.1 ± 0.7
9000g 3.5 ± 0.7
105,000 g 0.6 ± 0.2
105,000 g supernatant 93.8 ± 1.1
aAt 60 min after IV administration. Results are means ± SEM
offour individual determinations.
Table 4. Subceilular distribution ofHCPD-14C in liver fractions.a
Concn ofkidney (j.mole/g),
Fraction % of 14C in whole homogenate
Whole homogenate 100
900g 11.1 ± 1.9
9000g 7.1 ± 2.0
105,000 g 14.2 ± 2.1
105,000 g supernatant 67.5 + 2.2
aAt 60 min after IV administration. Results are means ± SEM
offour individual determinations.
Table 5. Effect of pre-exposure on HCPD dispositlon.a
HCPD-14C after 60 min, ,umole x 102
Organ Per organ Per g of tissue
Liver 25 ± 1 1.7 ± 0.1
Kidney 29 ± 3 8.3 ± 0.2
aRats were pretreated with HCPD (50 Ag/kg, PO, 3 days).
Tissue contents were determined 60 min after IV administration
of 5 ,umole HCPD-14C. Results are means ± SEM of three
individual determinations.
etc., by dialysis and extraction of the cytosol frac-
tions.
HCPD appears to be eliminated from the body
efficiently by urinary excretion. Although direct
evidence is not available, it appears that elimination
by expiration may be the major route ofremoval of
this compound. Subcellularly HCPD is predomi-
nantly associated with liver and kidney cytosol frac-
tions. HCPD is metabolized to at least four metabo-
lites. Although to a small extent, HCPD is also
eliminated via biliary excretion. Kinetics ofabsorp-
tion, via lungs and pulmonary elimination and via
kidney as well as any effects ofchronic exposure on
these organ systems should be examined in future
experiments.
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